| nintedanib / Generic mfg. |
ChiCTR2000031453: Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial |
|
|
| Not yet recruiting | 4 | 80 | | Nintedanib ;Placebo | Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University; Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | Novel Coronavirus Pneumonia (COVID-19) | | | | |
PINCER, NCT04856111: Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia |
|
|
| Active, not recruiting | 4 | 48 | RoW | Pirfenidone, Nintedanib | Postgraduate Institute of Medical Education and Research | Novel Coronavirus-induced Lung Fibrosis | 11/22 | 11/22 | | |
ENDCOV-I, NCT04619680: The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 |
|
|
| Completed | 4 | 103 | US | Nintedanib, Placebo | Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim | Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease | 02/24 | 03/24 | | |
| Active, not recruiting | 4 | 120 | RoW | Nintedanib, Standard of care | Post Graduate Institute of Medical Education and Research, Chandigarh | Sarcoidosis, Pulmonary | 12/25 | 01/26 | | |
| Recruiting | 4 | 134 | US | Nintedanib, OFEV, Placebo, Standard of Care | Rohit Aggarwal, MD, Boehringer Ingelheim | Myositis Associated Interstitial Lund Disease (MA-ILD) | 01/25 | 06/25 | | |
NCT03939520: Management of Progressive Disease in Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 4 | 378 | Europe | pirfenidone and nintedanib, pirfenidone or nintedanib | Hospices Civils de Lyon | Progressive Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
2015-004919-20: A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) Studio pilota sul Nintedanib nella Linfangioleiomiomatosi ( LAM ) |
|
|
| Ongoing | 3 | 30 | Europe | Capsule, soft, Ofev | MULTIMEDICA S.P.A., B.4.1 Azienda Farmaceutica: Boehringer Ingelheim Pharma GmbH &Co. KG | Female subjects affected by Llymphangioleiomyomatosis (LAM) La linfangioleiomiomatosi(LAM)è una malattia multisistemica che colpisce prevalentemente le donne in età fertile.E’ caratterizzata da proliferazione di cellule muscolari lisce anomale(cellule LAM)che causano la formazione di cisti aeree all’interno del polmone,alterazioni cistiche lungo il decorso dei vasi linfatici(linfangioleiomiomi)e angiomiolipomi, tumori benigni generalmente riscontrati nel rene.Può essere sporadica o interessare fino al 80% delle donne affette da Sclerosi Tuberosa (TSC)., ymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction and predominantly affects women, especially during child bearing years Malattia del polmone caratterizzata da sostituzione della normale architettura del polmone con cisti aeree., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-001747-31: A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2 Essai multicentrique, randomisé double aveugle contre placebo, évaluant l'efficacité du Nintedanib dans le traitement du Syndrome de Bronchiolite Oblitérante de grade 1-2 chez les patients transplantés pulmonaires. |
|
|
| Not yet recruiting | 3 | 80 | Europe | Capsule, OFEV | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation. Syndrome de Bronchiolite Oblitérante (SBO) de grade 1 ou 2 chez des patients patients greffés pulmonaires ., bronchiolitis obliterans syndrome Syndrome de Bronchiolite Oblitérante de grade 1-2, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004326-19: Management of Progressive Disease in Idiopathic Pulmonary Fibrosis Prise en charge pragmatique de la fibrose pulmonaire idiopathique en progression |
|
|
| Not yet recruiting | 3 | 378 | Europe | Capsule, Capsule, soft, pirfenidone, nintedanib | Hospices Civils de Lyon, Ministry of Health | Idiopathic pulmonary fibrosis fibrose pulmonaire idiopathique, Idiopathic pulmonary fibrosis Fibrose pulmonaire idiopathique, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-002114-40: Nintedanib for the treatment of pulmonary fibrosis induced by Covid-19 |
|
|
| Not yet recruiting | 3 | 250 | Europe | Capsule, soft, OFEV 150 mg, OFEV 100 mg | Assistance Publique - Hôpitaux de Paris, Ministery of Health | Patients 2 to 6 months after Covid-19 acute pneumonia, patients 2 to 3 months after acute pneumonitis induced Covid-19 infection, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | | | | |
| Recruiting | 3 | 250 | Europe | Nintedanib 150 MG [Ofev], Placebo, NaCl | Assistance Publique - Hôpitaux de Paris, Boehringer Ingelheim | SARS-Cov-2 Induced Pulmonary Fibrosis | 10/23 | 07/24 | | |
| Recruiting | 3 | 80 | Europe | Nintedanib, Placebo | Assistance Publique - Hôpitaux de Paris | Lung-transplant Recipients | 01/25 | 05/25 | | |
NINTOC-TU, NCT06297096: Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease |
|
|
| Not yet recruiting | 3 | 86 | Europe | Tocilizumab, Nintedanib, Standard therapy, mycophenolate mofetil, methotrexate | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Medical Research Agency, Poland | Systemic Sclerosis, Interstitial Lung Disease | 12/27 | 03/28 | | |
NCT05065190: A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis |
|
|
| Completed | 3 | 81 | RoW | nintedanib, Placebo | Boehringer Ingelheim | Lung Diseases, Interstitial | 04/24 | 05/24 | | |
NCT05067517: Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease |
|
|
| Not yet recruiting | 3 | 160 | US | Nintedanib, OFEV, Placebo | West Virginia University | Progressive Fibrosing Interstitial Lung Disease | 07/24 | 07/24 | | |
NCT05285982 / 2020-005554-23: A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) |
|
|
| Active, not recruiting | 3 | 54 | Europe, Canada, US, RoW | Nintedanib (Ofev®) | Boehringer Ingelheim | Lung Diseases, Interstitial | 07/25 | 08/25 | | |
ChiCTR2300070492: Nintedanib in Prevention of Pulmonary Fibrosis in Malignant Ovarian Germ Cell Tumor Patients Receiving Bleomycin: A randomized, double-blind, controlled trial |
|
|
| Not yet recruiting | 3 | 116 | | standard BEP regimen chemotherapy with nintedanib 150mg bid po till the end of treatment ;standard BEP regimen chemotherapy with plabeco 150mg bid po till the end of treatment | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Malignant Ovarian Germ Cell Tumor | | | | |
NCT05635071: Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions |
|
|
| Not yet recruiting | 2/3 | 90 | NA | Nintedanib 100 MG [Ofev], Nintedanib 100 MG Oral Capsule, Nintedanib 150 MG [Ofev], Nintedanib 150 MG Oral Capsule | Sixth Affiliated Hospital, Sun Yat-sen University | Uterine Adhesions | 07/24 | 12/24 | | |
2006-004528-35: A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer. |
|
|
| Ongoing | 2 | 120 | Europe | BIBF 1120, 50 mg, BIBF 1120, 200 mg, BIBW 2992, 5 mg, BIBW 2992, 20 mg, BIBF 1120, BIBW 2992, Capsule, soft, Film-coated tablet, Marca comercial no especificada - Ver sección D.2.2, Marca comercial no especificada- ver sección D.2.2 | Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim France SAS, Boehringer Ingelheim España, S.A., , Boehringer Ingelheim España, S.A. | Metastatic colorectal carcinoma, Metastatic colorectal carcinoma Cáncer colo-rectal metastásico., Diseases [C] - Cancer [C04] | | | | |
2012-004076-19: ENGOT-cx1/BGOG-cx1: "Randomized double-blind Phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma." |
|
|
| Ongoing | 2 | 120 | Europe | Nintedanib, BIBF1120, Capsule, soft, Concentrate for solution for infusion, Solution for infusion, PACLITAXEL SANDOZ GMBH - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 10 FLACONCINI DA 300MG/50ML, CARBOPLATINO SANDOZ GMBH - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 45ML | UZ Leuven / Belgian Gynaecological Oncology Group, UNIVERSITY HOSPITALS LEUVEN/BELGIAN GYNAECOLOGICAL ONCOLOGY GROUP, BGOG, Boehringer Ingelheim (grant + IMP), Belgian Gynaecological Oncology Group (BGOG) | Advanced or recurrent cervical carcinoma, Advanced or recurrent cervical carcinoma, Diseases [C] - Cancer [C04] | | | | |
2012-004895-21: A study to investigate a new drug called Nintedanib for patients who have bladder cancer that has spread to the deeper walls of the bladder |
|
|
| Ongoing | 2 | 120 | Europe | Nintedanib, BIBF1120, Capsule, soft | The Clatterbridge Cancer Centre NHS Foundation Trust, Boehringer Ingelheim Ltd. | Muscle invasive bladder cancer - localised muscle invasive carcinoma (T2-T4a N0 M0), Bladder cancer that has spread to the deeper walls of the bladder, Diseases [C] - Cancer [C04] | | | | |
2013-004324-11: Study with BIBF1120 in lung canger patients with an abnormal fibroblast growth factor-1 receptor (NVALT-15 study) |
|
|
| Ongoing | 2 | 80 | Europe | Vargatef, BIBF1120, Capsule, soft, Vargatef | Stichting NVALT studies, Stichting NVALT studies | Non small cell lung cancer, Lung cancer, Diseases [C] - Cancer [C04] | | | | |
NCT02399215: Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors |
|
|
| Completed | 2 | 32 | US | Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment | Roswell Park Cancer Institute, National Comprehensive Cancer Network | Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm | 09/19 | 08/22 | | |
|
NCT02299141: Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Nintedanib, Ofev, BIBF 1120, Vargatef | Washington University School of Medicine, National Comprehensive Cancer Network | Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer | 01/20 | 12/24 | | |
2015-000475-27: Treatment of no squamous non small cell lung cancer Traitement du cancer bronchique non à petites cellules |
|
|
| Not yet recruiting | 2 | 59 | Europe | Capsule, Injection, Vergatef, TAXOTERE | CHU de Limoges, CHU de Limoges, laboratoire Boehringer Ingelheim | No squamous non small cell lung, Lung cancer, Diseases [C] - Cancer [C04] | | | | |
2016-000109-35: A Phase I-II Trial of Combination Nab-paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma - N3 Study |
|
|
| Not yet recruiting | 2 | 194 | Europe | VARGATEF, Abraxane, Capsule, soft, Powder for suspension for injection, VARGATEF, Abraxane | Royal Marsden NHS Foundation Trust, Boehringer Ingelheim Limited, Celgene International II Sàrl | Relpased advanced or metastatic non-small cell lung cancer of adenocarcinoma histology, Advanced lung cancer, Diseases [C] - Cancer [C04] | | | | |
NCT02009579: ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer |
|
|
| Active, not recruiting | 2 | 120 | Europe | Nintedanib, Vargatef, Placebo | Belgian Gynaecological Oncology Group, Grupo Español de Investigación en Cáncer de Ovario, Mario Negri Gynecologic Oncology group (MaNGO), Multicenter Italian Trials in Ovarian Cancer (MITO), North Eastern German Society of Gynaecological Oncology | Uterine Cervical Neoplasms | 01/21 | 10/23 | | |
| Completed | 2 | 61 | Europe | Nintedanib 150 mg and 100 mg soft capsules, Oral treatment of placebo soft capsule | Hospices Civils de Lyon | Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease | 02/23 | 02/23 | | |
NCT05444998: Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer |
|
|
| Not yet recruiting | 2 | 20 | NA | Intuzumab, pyrrolidone, nab-paclitaxel | Xijing Hospital | Breast Cancer | 08/23 | 12/23 | | |
NCT05373914: RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Not yet recruiting | 2 | 200 | NA | Cudetaxestat (BLD-0409), Cudetaxestat, Control: Matching Placebo | Blade Therapeutics | Idiopathic Pulmonary Fibrosis | 12/23 | 03/24 | | |
| Active, not recruiting | 2 | 37 | Europe | Nintedanib, Placebo | European Organisation for Research and Treatment of Cancer - EORTC | Malignant Pleural Mesothelioma | 03/24 | 03/24 | | |
EPISTOP, NCT04976036: Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients |
|
|
| Recruiting | 2 | 48 | Europe | Nintedanib, Placebo | Dr. Romain Lazor, Boehringer Ingelheim | Telangiectasia, Hereditary Hemorrhagic | 04/24 | 09/24 | | |
NINBOST2018, NCT03805477: Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 2 | 20 | Europe, RoW | Nintedanib | University Hospital, Basel, Switzerland | Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO) | 08/25 | 08/25 | | |
NiPPs, NCT04161014: The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial |
|
|
| Recruiting | 2 | 100 | RoW | Nintedanib 150 MG [Ofev] | Holdsworth House Medical Practice, Boehringer Ingelheim | Pneumoconiosis Coal, Asbestosis, Silicosis | 12/24 | 02/25 | | |
NCT02496585: Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis |
|
|
| Completed | 2 | 33 | US | Nintedanib, BIBF 1120, Prednisone, Placebo | Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim | Lung Cancer, Lung Metastases | 04/24 | 04/24 | | |
NCT06071013: Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients |
|
|
| Not yet recruiting | 2 | 20 | NA | Nintedanib, gefitinib, erlotinib, afatinib | China Medical University Hospital | Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation | 08/26 | 08/26 | | |
2016-000877-19: A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours. |
|
|
| Ongoing | 1/2 | 65 | Europe | DTX-SPL8783, Concentrate for solution for infusion, Powder and solution for solution for injection | Starpharma Pty Ltd., Starpharma Pty Ltd. | Locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC)., Advanced malignant solid tumours., Diseases [C] - Cancer [C04] | | | | |
NintNivo, NCT04046614: Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology |
|
|
| Completed | 1/2 | 56 | Europe | nintedanib-nivolumab combination therapy | AIO-Studien-gGmbH | Adenocarcinoma of the Lung | 05/23 | 09/23 | | |
2021-001555-14: Assessment of the effect of Wharton's jelly mesenchymal stem cellpreparation (WJMSCs) in the treatment of fibrotic interstitial lungdiseases Ocena wpływu preparatu mezenchymalnych komórek macierzystychgalarety Whartona (WJMSCs) w leczeniu zwłókniającychśródmiąższowych chorób płuc |
|
|
| Not yet recruiting | 1/2 | 45 | Europe | allogeneic mesenchymal stem cells derived from Wharton’s jelly, Allogeneic WJ-MSC, Suspension for injection, Tablet, Capsule, soft, Esbriet, Ofev 100mg, Ofev 150mg | Medical University of Gdańsk, Medical Reaserch Agency | fibrotic interstitial lung disease zwłókniająca śródmiąższowa choroba płuc, idiopathic pulmonry fibrosis and pulmonary fibrosis after COVID-19 Samoistne włóknienie płuc oraz włóknienie płuc po COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT03377023: Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 68 | US | Nivolumab, Opdivo®, Ipilimumab, Yervoy®, Nintedanib, Vargatef®, Ofev®, BIBF1120 | H. Lee Moffitt Cancer Center and Research Institute | Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic | 11/24 | 11/25 | | |
| Terminated | 1/2 | 14 | US | Nintedanib, Ofev, Vargatef | University of Texas Southwestern Medical Center, Boehringer Ingelheim, The University of Texas Health Science Center at San Antonio, South Plains Oncology Consortium | Cancer of Pancreas | 10/21 | 10/21 | | |
NCT03513484: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1 | 44 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef | Northwestern University, Robert H. Lurie Cancer Center, Boehringer Ingelheim, National Cancer Institute (NCI) | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 12/25 | 01/27 | | |
NCT05830799: A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers |
|
|
| Completed | 1 | 18 | Europe | Drug Drug Interaction, Caffeine, Koffein Meda, Tolbutamide, Tolbutamide CF, Midazolam, Midazolam APL, Nintedanib, Ofev | Vicore Pharma AB | Drug Interaction | 05/23 | 05/23 | | |
NCT05817240: A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects |
|
|
| Completed | 1 | 21 | RoW | taladegib, ENV-101, nintedanib | Endeavor Biomedicines, Inc. | Idiopathic Pulmonary Fibrosis | 06/23 | 06/23 | | |
NCT05644600: A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants. |
|
|
| Terminated | 1 | 18 | Europe | Nintedanib, AZD5055 | AstraZeneca, Parexel | Healthy Subjects | 07/23 | 07/23 | | |
NCT06070610: A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood |
|
|
| Completed | 1 | 14 | Europe | BI 1015550, Nintedanib, Ofev®, Pirfenidone, Esbriet® | Boehringer Ingelheim | Healthy | 12/23 | 12/23 | | |
NCT02225405: Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer |
|
|
| Completed | 1 | 26 | US | Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | 05/24 | 05/24 | | |
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients |
|
|
| Recruiting | 1 | 50 | US | EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone | Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington | Idiopathic Pulmonary Fibrosis | 03/25 | 03/25 | | |
| Recruiting | 1 | 221 | Europe | Nintedanib, Pembrolizumab | Gustave Roussy, Cancer Campus, Grand Paris | Patients With Any Advanced Solid Tumors | 11/25 | 11/28 | | |
NCT02230982: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| No Longer Available | N/A | | RoW | nintedanib | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | | | | |
NCT04739150: An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options |
|
|
| No Longer Available | N/A | | Europe | nintedanib, Ofev® | Boehringer Ingelheim | Lung Diseases, Interstitial | | | | |
ChiCTR2000037390: A randomized controlled study of body stereotactic radiotherapy combined with nintedanib in the treatment of early stage non-small cell lung cancer with interstitial lung disease |
|
|
| Recruiting | N/A | 63 | | SBRT vs SBRT and nintedanib ;SBRT vs SBRT and nintedanib ;SBRT vs SBRT and nintedanib | Shanghai Pulmonary Hospital; Level of the institution：, Shanghai Shenkang Three-year Action Plan | early stage non-small cell lung cancer with interstitial lung disease | | | | |
NCT05335278: Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study |
|
|
| Recruiting | N/A | 25 | Canada | Nintedanib 150 milligrams [Ofev] | McGill University Health Centre/Research Institute of the McGill University Health Centre | Interstitial Lung Disease, Myopathy, Inflammatory | 12/22 | 05/23 | | |
QUALIFY IPF, NCT03710824: Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib |
|
|
| Completed | N/A | 180 | Europe | Nintedanib | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 02/23 | 02/23 | | |
NCT05870956: Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients |
|
|
| Completed | N/A | 1798 | US | Nintedanib, Ofev® | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 06/23 | 06/23 | | |
NCT05779007: Dose Reduction and Discontinuation With Anti-Fibrotic Medications |
|
|
| Completed | N/A | 2778 | US | Pirfenidone, Nintedanib | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 07/23 | 07/23 | | |
NCT02607722: All-Case Surveillance of Ofev in Patients With IPF in Japan |
|
|
| Completed | N/A | 10117 | Japan | Nintedanib | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 05/23 | 05/23 | | |
INREAL, NCT04702893: - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation |
|
|
| Active, not recruiting | N/A | 108 | Europe | Nintedanib, Ofev® | Boehringer Ingelheim | Lung Diseases, Interstitial | 04/24 | 06/24 | | |
HOPE-IPF, NCT02551068: High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib |
|
|
| Recruiting | N/A | 88 | Canada | 60% Oxygen, Standard of Care | University of British Columbia, Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 04/24 | 04/25 | | |
BIOFEV, NCT05755308: Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | N/A | 114 | Europe | Autologous FMT, Placebo FMT | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Idiopathic Pulmonary Fibrosis | 04/24 | 04/26 | | |
NCT06200714: A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib |
|
|
| Recruiting | N/A | 100 | Europe | | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis, Diarrhoea | 04/25 | 04/25 | | |
NCT04559581: Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan |
|
|
| Active, not recruiting | N/A | 425 | Japan | Nintedanib, Ofev | Boehringer Ingelheim | Lung Diseases, Interstitial | 09/24 | 12/24 | | |
| Active, not recruiting | N/A | 816 | Europe | treatment | Boehringer Ingelheim | Carcinoma, Non-Small-Cell Lung | 12/24 | 01/25 | | |
NCT05151640: INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation |
|
|
| Recruiting | N/A | 123 | Europe, RoW | Nintedanib | Boehringer Ingelheim | Lung Diseases, Interstitial | 06/25 | 06/25 | | |
NCT04614441: NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib |
|
|
| Active, not recruiting | N/A | 214 | RoW | OFEV® | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 07/25 | 07/25 | | |
NCT04325217: Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan |
|
|
| Active, not recruiting | N/A | 585 | Japan | Nintedanib, Ofev® | Boehringer Ingelheim | Lung Diseases, Interstitial | 06/26 | 09/26 | | |
| Withdrawn | N/A | 800 | NA | nintedanib, pirfenidone | Boehringer Ingelheim, China-Japan Friendship Hospital | Pulmonary Fibrosis | 09/26 | 09/26 | | |
INTENSE, NCT05503030: Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients |
|
|
| Recruiting | N/A | 120 | Europe | Nintedanib | Boehringer Ingelheim | Lung Diseases, Interstitial | 12/26 | 12/26 | | |